We are live on
!
Find out more
DCM
DAFNA Capital Management Portfolio holdings
AUM
$440M
1-Year Est. Return
109.12%
This Fund
S&P 500
This Quarter
Est. Return
-10.55%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$353M
AUM Growth
-$40.7M
(-10%)
Cap. Flow
+$13.6M
Cap. Flow
% of AUM
3.86%
Top 10 Holdings %
Top 10 Hldgs %
52.84%
Holding
90
New
8
Increased
24
Reduced
15
Closed
7
Top Buys
| 1 |
Arcus Biosciences
RCUS
|
+$4.3M |
| 2 |
Stoke Therapeutics
STOK
|
+$2.54M |
| 3 |
Denali Therapeutics
DNLI
|
+$2.45M |
| 4 |
Inogen
INGN
|
+$2.35M |
| 5 |
Oric Pharmaceuticals
ORIC
|
+$2.12M |
Top Sells
| 1 |
Ascendis Pharma A/S
ASND
|
+$3.28M |
| 2 |
Axogen
AXGN
|
+$3M |
| 3 |
AtriCure
ATRC
|
+$1.83M |
| 4 |
BioCryst Pharmaceuticals
BCRX
|
+$877K |
| 5 |
Alkermes
ALKS
|
+$864K |
Sector Composition
| 1 | Healthcare | 85.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
State Street SPDR S&P Biotech ETF
XBI
$10.5B
| $32.8M | 9.3% |
404,505
+7,000
| +2% | +$626K |
|
2
Stereotaxis
STXS
$161M
| $24.1M | 6.83% |
13,680,554
| – | – |
|
3
Revolution Medicines
RVMD
$39.2B
| $23.2M | 6.58% |
656,176
+25,000
| +4% | +$1.01M |
|
|
MRUS
4
DELISTED
Merus
MRUS
| $19.4M | 5.51% |
461,804
+10,000
| +2% | +$436K |
|
|
5
AtriCure
ATRC
$1.76B
| $19.1M | 5.42% |
592,273
-49,400
| -8% | -$1.83M |
|
6
Cytokinetics
CYTK
$11.2B
| $16M | 4.54% |
398,100
| – | – |
|
|
BPMC
7
DELISTED
Blueprint Medicines
BPMC
| $13.5M | 3.82% |
152,263
+2,500
| +2% | +$244K |
|
8
iShares Biotechnology ETF
IBB
$9.2B
| $13.1M | 3.72% |
102,500
| – | – |
|
|
9
Axogen
AXGN
$2.07B
| $12.6M | 3.57% |
680,782
-166,100
| -20% | -$3M |
|
|
10
Ascendis Pharma A/S
ASND
$17.4B
| $12.5M | 3.55% |
80,398
-22,957
| -22% | -$3.28M |
|
11
IDEAYA Biosciences
IDYA
$3.54B
| $9.65M | 2.74% |
589,330
+90,503
| +18% | +$1.93M |
|
12
Xenon Pharmaceuticals
XENE
$6.52B
| $9.18M | 2.6% |
273,739
| – | – |
|
|
KALV
13
DELISTED
KalVista Pharmaceuticals
KALV
| $8.68M | 2.46% |
752,359
-59,319
| -7% | -$605K |
|
14
Neurocrine Biosciences
NBIX
$17.2B
| $7.92M | 2.25% |
71,615
| – | – |
|
15
Syndax Pharmaceuticals
SNDX
$2.12B
| $6.69M | 1.9% |
544,502
+2,500
| +0.5% | +$35.3K |
|
|
DAWN
16
DELISTED
Day One Biopharmaceuticals
DAWN
| $5.8M | 1.64% |
731,363
| – | – |
|
17
Tandem Diabetes Care
TNDM
$1.07B
| $5.64M | 1.6% |
294,208
+71,000
| +32% | +$2.08M |
|
18
UroGen Pharma
URGN
$1.94B
| $5.45M | 1.54% |
492,515
| – | – |
|
19
Biohaven
BHVN
$2.23B
| $5.29M | 1.5% |
220,235
| – | – |
|
20
Mineralys Therapeutics
MLYS
$2.38B
| $4.91M | 1.39% |
309,200
+162,700
| +111% | +$1.87M |
|
|
21
Arcus Biosciences
RCUS
$3.52B
| $4.91M | 1.39% |
625,126
+370,909
| +146% | +$4.3M |
|
22
DexCom
DXCM
$28.6B
| $4.48M | 1.27% |
65,552
| – | – |
|
|
23
BioCryst Pharmaceuticals
BCRX
$2.4B
| $4.19M | 1.19% |
558,255
-108,745
| -16% | -$877K |
|
24
Edgewise Therapeutics
EWTX
$4.32B
| $4.03M | 1.14% |
183,140
-4,000
| -2% | -$105K |
|
|
LKFT
25
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.93B
| $3.27M | 0.93% |
130,175
| – | – |
|
Similar funds
FGWP
STCG
SCP
CAAM
AWM
HCM
CPW
DWML